other material
confidence high
sentiment positive
materiality 0.70
Supernus reports positive interim Phase 2a data for SPN-817 in treatment-resistant seizures
SUPERNUS PHARMACEUTICALS, INC.
- 75% median focal seizure reduction at 3-4 mg BID in maintenance period; 86% reduction in open-label extension.
- 81% of focal-seizure subjects had ≥30% reduction; 63% had ≥50% reduction in maintenance period.
- Discontinuation rate due to AEs was 22% in titration and 2.4% in maintenance; common AEs: nausea, diarrhea, headache.
- Company plans to initiate Phase 2b study before year-end 2024; full Phase 2a topline results expected H2 2024.
- CEO states interim data provide strong evidence of clinical utility and potential differentiated treatment option.